Related Experiment Video

Updated: Feb 7, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.7K

Using PARP Inhibitors in Advanced Ovarian Cancer

Roisin E O'Cearbhaill

    Oncology (Williston Park, N.Y.)
    |August 7, 2018
    PubMed

    Insights

    Poly(ADP-ribose) polymerase (PARP) inhibitors offer new ovarian cancer treatments. These drugs, like olaparib and rucaparib, are effective but require careful management of side effects for optimal patient care.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Poly(ADP-ribose) polymerase (PARP) proteins are crucial for DNA repair pathways.
    • PARP inhibition selectively targets cancer cells with defective DNA repair mechanisms.
    • PARP inhibitors have emerged as a significant advancement in ovarian cancer treatment.

    Purpose of the Study:

    • To review the current landscape of PARP inhibitors in ovarian cancer management.
    • To discuss the clinical implications of FDA-approved PARP inhibitors (olaparib, rucaparib, niraparib).
    • To highlight challenges and future directions in utilizing PARP inhibitors.

    Main Methods:

    • Literature review of PARP inhibitors in ovarian cancer.
    • Analysis of FDA approvals and clinical guidelines.
    • Discussion of therapeutic strategies and adverse effect management.

    Main Results:

    • Olaparib and rucaparib are approved for BRCA-associated recurrent ovarian cancer.
    • Olaparib, rucaparib, and niraparib are approved for maintenance therapy post-chemotherapy.
    • PARP inhibitors represent a paradigm shift in recurrent ovarian cancer treatment.

    Conclusions:

    • PARP inhibitors have transformed ovarian cancer management, offering new therapeutic options.
    • Clinicians face challenges in individualizing treatment and managing side effects like nausea and fatigue.
    • Future research should focus on safe combination therapies involving PARP inhibitors.

    More Related Videos

    Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

    Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

    Published on: December 5, 2020

    3.0K
    Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

    Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

    Published on: February 24, 2023

    2.3K

    Related Concept Videos

    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    11.0K
    Ovarian Cycle01:27

    Ovarian Cycle

    The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
    4.0K
    Overview of Advanced Functional Groups02:22

    Overview of Advanced Functional Groups


    Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
    Types of Advanced Functional Groups
    The table below summarizes some of the major functional groups in organic chemistry.
    30.1K
    Extraction: Advanced Methods00:56

    Extraction: Advanced Methods

    Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
    1.2K
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    685
    Hormonal Control of the Ovarian Cycle01:30

    Hormonal Control of the Ovarian Cycle

    The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
    Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
    6.9K